Table 3.

Association of Clinical and Immunohistochemical Variables With Progression-Free Survival Based on Cox Proportional Hazards Regression Models

	Univariate Analysis		Multivariable Analysisa
Variable	HR (95% CI)	P	Adjusted HR (95% CI)	Adjusted P
Preoperative PSAb
Continuous variable	1.01 (0.99-1.04)	.213	0.98 (0.95-1.01)	.115
Seminal vesicle invasion
Positive vs negativec	2.18 (1.11-4.29)	.024	1.43 (0.65-3.14)	.378
Surgical margin status
Positive vs negativec	1.03 (0.55-1.94)	.931	1.18 (0.34-4.12)	.799
Lymph node involvement
Positive vs negativec	1.19 (0.64-2.22)	.585	2.45 (0.77-7.83)	.130
Pathologic Gleason sumc
9-10 vs 7	2.18 (1.11-4.29)	.023	1.74 (0.64-4.75)	.277
8 vs 7	1.65 (0.63-4.31)	.305	1.61 (0.46-5.72)	.460
9-10 vs 8	1.32 (0.53-3.28)	.547	1.04 (0.30-3.60)	.946
ERG
Presence vs absencec	0.86 (0.47-1.58)	.631	1.52 (0.66-3.51)	.330
Aktb
Continuous variable	1.16 (0.78-1.74)	.460	1.22 (0.75-2.01)	.426
S6b
Continuous variable	1.12 (0.76-1.65)	.574	–	–
mTORb
Continuous variable	1.14 (0.76-1.70)	.519	–	–
MYCb
Continuous variable	0.63 (0.41-0.97)	.036	0.28 (0.13-0.61)	.001
Ki67b
Continuous variable	1.26 (1.14-1.40)	< .0001	1.43 (1.21-1.68)	< .0001
p53
Presence vs absencec	1.21 (0.62-2.33)	.578	0.61 (0.27-1.40)	.244
PTEN
Loss vs presencec	1.82 (1.08-3.66)	.031	2.93 (1.08-7.92)	.035

Abbreviations: CI, confidence interval; ERG, v-ets erythroblastosis virus E26 oncogene homolog; HR, hazard ratio; Ki67, antigen KI-67; mTOR, mammalian target of rapamycin; p53, tumor protein p53; PSA, prostate-specific antigen; PTEN, phosphatase and tensin homolog; S6, S6 ribosomal protein.

^aThe multivariable analysis excluded S6 and mTOR to avoid multicollinearity.

^bContinuous variable.

^cCategorical variable.